SCHEMBL6482791

SCHEMBL6482791

Cc1c(F)cccc1CNc1ccc2oc3cccnc3c2c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.42
L3MBTL1 Q9Y468 6/20 0.42
KMT2A Q03164 5/20 0.42
MAPT P10636 5/20 0.42
ALDH1A1 P00352 3/20 0.42
TDP1 Q9NUW8 3/20 0.42
LMNA P02545 3/20 0.39
MEN1 O00255 2/20 0.39
USP2 O75604 2/20 0.39
ALOX12 P18054 2/20 0.39
MPI P34949 1/20 0.39
RECQL P46063 1/20 0.39
NTRK1 P04629 1/20 0.39
NTRK3 Q16288 1/20 0.39
NTRK2 Q16620 1/20 0.39
VCP P55072 1/20 0.39
LRRK2 Q5S007 1/20 0.38
CDC7 O00311 1/20 0.38
CCNE1 P24864 1/20 0.38
CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6527731 0.90 KDM4E (0.48) KDM4EL3MBTL1KMT2AMAPTALDH1A1
SCHEMBL6486876 0.85 ALDH1A1 (0.41) KDM4EL3MBTL1KMT2AMAPTALDH1A1
SCHEMBL6492990 0.83 RXFP1 (0.44) KDM4EL3MBTL1KMT2AMAPTALDH1A1
SCHEMBL6494767 0.81 MAPT (0.42) KDM4EL3MBTL1KMT2AMAPTALDH1A1
SCHEMBL6482769 0.81 MAOB (0.41) KDM4EL3MBTL1KMT2AMAPTALDH1A1
SCHEMBL6494366 0.79 MAOB (0.45) KDM4EL3MBTL1KMT2AMAPTALDH1A1
SCHEMBL6483043 0.79 CYP2C9 (0.48) KDM4EL3MBTL1KMT2AMAPTALDH1A1
SCHEMBL6483671 0.73 MEN1 (0.55) KDM4EL3MBTL1KMT2AMAPTALDH1A1
SCHEMBL6483738 0.73 PDE4D (0.33) KDM4EL3MBTL1KMT2AMEN1ATM
SCHEMBL6481773 0.72 KMT2A (0.45) KDM4EL3MBTL1KMT2AMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050075332-A1 Tricyclic compounds with antiviral activity WARNER LAMBERT COMPANY 2005-04-07 US claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US claimed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US claimed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP claimed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO claimed
US-6800656-B2 Tricyclic compounds and method of treating herpes virus WARNER LAMBERT COMPANY 2004-10-05 US disclosed
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus BOOTH RICHARD JOHN (US) 2003-12-11 US disclosed
EP-1248777-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2002-10-16 EP disclosed
WO-2001051479-A2 TRICYCLIC COMPOUNDS WITH ANTIVIRAL ACTIVITY WARNER-LAMBERT COMPANY (US) 2001-07-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030229073-A1 Tricyclic compounds and method of treating herpes virus HDAC8, ZC3HAV1, ZCCHC8 KDM4E 1279/4885L3MBTL1 3832/4885KMT2A 412/4885
US-20050075332-A1 Tricyclic compounds with antiviral activity HDAC8, CDK8, ZC3HAV1 KDM4E 1476/4885L3MBTL1 2831/4885KMT2A 770/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.